Study 3: Vitiligo & Alopecia Areata

Consider taking part in a clinical research study of a potential new treatment for Vitiligo and Alopecia Areata.

The purpose of this study is to explore whether an investigational drug can improve results for people with Vitiligo and Alopecia Areata by destroying the cells that cause their autoimmune disease.

You may be eligible to participate if you meet the following eligibility criteria:

• Have been diagnosed with Vitiligo for at least 3 months.

• Your vitiligo covers 4% to 60% of your body excluding the palms of your hands, top of your fingers and thumbs, soles of your feet and top side of your feet.

• Aged 18 years and older.

or

• Have been diagnosed with Alopecia Areata between 6 months and 10 years ago.

• Agree to not use adhesive wigs (other than banded perimeter wigs) during the study.

• Aged 18 years and older.

The trial will consist of a screening period of up to 28 days and, if you are eligible to participate in the study, you will then receive up to 24 weeks (6 months) of treatment, followed by an additional 24 weeks (6 months) of follow-up visits. Participants who successfully complete dosing may receive additional treatment through an extension study. You will be reimbursed for your time and travel, while supporting medical research.

By contacting us, you are under no obligation to take part in the study. Dermatology Institute of Victoria, 8-10 Howitt Street, South Yarra VIC 3141. Daniela Borzillo danni@div.net.au or (03) 9826 4966.